CEO Interview: Novartis' Dan Vasella
Novartis has done better than most Pharmas over the past five years, though shareholders are still dissatisfied. But CEO Dan Vasella continues playing for the long-term -- pursuing R&D innovation and cost-effective dealmaking, all within a relatively conservative strategic framework.
You may also be interested in...
Indication for non-transfusion dependent thalassemia, a cluster of inherited blood disorders that cause mild anemia, will be reviewed by FDA’s Oncologic Drugs Advisory Committee Nov. 8.
In a move that was somewhat abrupt, but hardly surprising, Novartis AG in late January announced that Joe Jimenez, who currently runs Novartis Pharma AG, would become the company's CEO, effective February 1. Long-time chairman and CEO David Vasella will remain as chairman. The announcement brings some closure to a process that began officially more than a year ago, as Novartis worked to get its succession planning right
The news eclipses reports of a strong 2009, in which Novartis received 30 major regulatory approvals, and saw sales grow across major divisions